Bayforest Capital Ltd Has $160,000 Holdings in Insulet Corporation $PODD

by · The Markets Daily

Bayforest Capital Ltd grew its holdings in Insulet Corporation (NASDAQ:PODD – Free Report) by 106.8% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 608 shares of the medical instruments supplier’s stock after purchasing an additional 314 shares during the period. Bayforest Capital Ltd’s holdings in Insulet were worth $160,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in PODD. Larson Financial Group LLC raised its holdings in shares of Insulet by 426.3% in the first quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier’s stock valued at $26,000 after purchasing an additional 81 shares during the last quarter. Zions Bancorporation National Association UT acquired a new stake in shares of Insulet in the first quarter valued at approximately $26,000. SouthState Corp raised its holdings in shares of Insulet by 253.3% in the first quarter. SouthState Corp now owns 106 shares of the medical instruments supplier’s stock valued at $28,000 after purchasing an additional 76 shares during the last quarter. Ramirez Asset Management Inc. acquired a new stake in shares of Insulet in the first quarter valued at approximately $53,000. Finally, NewEdge Advisors LLC raised its holdings in shares of Insulet by 44.8% in the first quarter. NewEdge Advisors LLC now owns 207 shares of the medical instruments supplier’s stock valued at $54,000 after purchasing an additional 64 shares during the last quarter.

Insiders Place Their Bets

In other Insulet news, SVP Laetitia Cousin sold 797 shares of Insulet stock in a transaction on Monday, September 8th. The shares were sold at an average price of $348.81, for a total transaction of $278,001.57. Following the completion of the transaction, the senior vice president directly owned 3,890 shares of the company’s stock, valued at $1,356,870.90. The trade was a 17.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Prem Singh sold 687 shares of Insulet stock in a transaction on Monday, September 8th. The stock was sold at an average price of $347.49, for a total transaction of $238,725.63. Following the transaction, the senior vice president directly owned 3,456 shares of the company’s stock, valued at approximately $1,200,925.44. This trade represents a 16.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.39% of the company’s stock.

Insulet Trading Up 1.1%

PODD stock opened at $341.78 on Friday. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81. The company has a fifty day moving average price of $311.59 and a two-hundred day moving average price of $291.99. Insulet Corporation has a one year low of $225.37 and a one year high of $353.50. The stock has a market cap of $24.06 billion, a price-to-earnings ratio of 103.88, a price-to-earnings-growth ratio of 2.81 and a beta of 1.36.

Insulet (NASDAQ:PODD – Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 EPS for the quarter, topping analysts’ consensus estimates of $0.92 by $0.25. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The firm had revenue of $649.10 million during the quarter, compared to analysts’ expectations of $612.31 million. During the same period in the previous year, the business posted $0.55 earnings per share. The company’s revenue for the quarter was up 32.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Equities analysts anticipate that Insulet Corporation will post 3.92 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on PODD. Barclays lifted their price objective on shares of Insulet from $266.00 to $300.00 and gave the company an “equal weight” rating in a report on Thursday, August 21st. Sanford C. Bernstein reissued an “outperform” rating on shares of Insulet in a research note on Friday, May 16th. Canaccord Genuity Group raised their target price on shares of Insulet from $331.00 to $353.00 and gave the company a “buy” rating in a research note on Friday, August 8th. Royal Bank Of Canada raised their target price on shares of Insulet from $330.00 to $350.00 and gave the company an “outperform” rating in a research note on Friday, August 8th. Finally, Wells Fargo & Company raised their target price on shares of Insulet from $330.00 to $350.00 and gave the company an “overweight” rating in a research note on Friday, August 8th. Sixteen analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $335.12.

Check Out Our Latest Research Report on Insulet

Insulet Company Profile

(Free Report)

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

Featured Articles